ProCE Banner Activity

Workshops With Experts: Advances to Improve Clinical Outcomes for Veterans With Pancreatic Cancer

Multimedia
In this interactive on-demand webcast, expert faculty discuss best practices and emerging strategies in the treatment of patients with newly diagnosed or progressive advanced pancreatic cancer.

Released: April 15, 2021

Expiration: April 14, 2022

No longer available for credit.

Share

Faculty

Andrew H. Ko

Andrew H. Ko, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Ipsen Biopharmaceuticals Inc

Learning Objectives

  • Consider efficacy and safety evidence as well as patient characteristics and preferences to individualize therapeutic strategies for patients with newly diagnosed pancreatic cancer and advanced pancreatic cancer following first-line systemic therapy based on available data and treatment guidelines (maintenance or progression)
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations 
  • Appraise the rationale for available/emerging data for the use of novel chemotherapy platforms, PARP inhibitors, immunotherapy (and immunotherapy-based combinations), stroma-targeting agents, and tumor treating fields therapy (TTFields), and others for pancreatic cancer
  • Manage disease-related and treatment-related symptoms for patients with advanced pancreatic cancer
  • Identify patients suitable for enrollment on ongoing clinical studies of emerging investigational agents and treatment strategies in advanced pancreatic cancer

Faculty Disclosure

Primary Author

Andrew H. Ko, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Andrew H. Ko, MD, has disclosed that he has received funds for research support paid to his institution from AbGenomics, Apexigen, Astellas, Bristol-Myers Squibb, Celgene, Merck, and Roche/Genentech and has received consulting fees from Erytech, Imugene, Ipsen, Roche/Genentech, and SynCore.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.